| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $90.00 | ||
| 25 mg | $325.00 |
ZT-1a (212135-62-1) is a non-ATP competitive inhibitor (IC50 = 44.3 µM @ 0.01 mM ATP) of SPAK kinase (STK39), a master regulator of cation-Cl– cotransporters.1 It attenuated cerebral edema, protected against ischemic brain damage, and improved post-ischemic neurological outcomes in mouse models of stroke.1,2 ZT-1a showed neuroprotective effects in mouse models of vascular dementia3 and multiple sclerosis4. It inhibited the progression of hepatocellular carcinoma in rodent models and showed synergistic effects with PD-1 antibodies by helping to prevent tumor microenvironment immune exhaustion.5
References/Citations:
C22H15Cl3N2O2
>98% HPLC
NMR: (Conforms)
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
ZT-1a (212135-62-1) is a non-ATP competitive inhibitor (IC50 = 44.3 µM @ 0.01 mM ATP) of SPAK kinase (STK39), a master regulator of cation-Cl– cotransporters.1 It attenuated cerebral edema, protected against ischemic brain damage, and improved post-ischemic neurological outcomes in mouse models of stroke.1,2 ZT-1a showed neuroprotective effects in mouse models of vascular dementia3 and multiple sclerosis4. It inhibited the progression of hepatocellular carcinoma in rodent models and showed synergistic effects with PD-1 antibodies by helping to prevent tumor microenvironment immune exhaustion.5
References/Citations:
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
BOGO